Public dataset
Recorded source agreement and disagreement
Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.
- Public rows
- 1,681
- Generated
- Schema version
- source-consensus/2
Coverage
What this run contains
- Compared medicine fields
- 1,681
- Agree
- 1,282
- Differ
- 0
- Not comparable
- 12
- Insufficient context
- 387
- Fields represented
- 5
- bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
Method
How the rows were made
- Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
- One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
- Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
- not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
- The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
- Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
- documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.
Limits
Read these before using a row
- Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
- The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
- Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
- Only the recorded fields and source documents in this snapshot are compared.
- A source count is the number of retained source records in the row, not a count of independent experiments.
Provenance
Source examples
abacavir · bioavailability · agree
15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)The geometric mean absolute bioavailability of the tablet was 83%.
alemtuzumab · volumeOfDistribution · not_comparable
2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).
abiraterone · halfLife · insufficient_context
31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)
FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.
Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.
Schema
Fields in the public projection
| Field | Type | Meaning |
|---|---|---|
| medicineSlug | string | Stable RNAWiki medicine route key. |
| field | string | Recorded pharmacokinetic field being compared. |
| comparisonState | string | agree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero. |
| comparisonReasons | string[] | Deterministic codes explaining the state. |
| documentsExamined | number | Recorded source documents considered for the field. |
| sourceCount | number | Recorded source readings represented. |
| agreementRate | number | Share represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability. |
| readings | consensus-reading[] | Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt. |
Reader
Search and filter the rows
Showing 441–450 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.
Projected row 441
- Medicine slug
- diltiazem
- Compared field
- bioavailability
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 111
- Source count
- 94
- Agreement rate
- 0.989362
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 93
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 93 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc2b889-8443-4f7f-83be-86c68e179804 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1042fa13-e6af-46b9-8008-6c941f0978b1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56573e9d-7bd2-694c-cd6d-26039590e548 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5460158f-7782-45f4-89b1-f84e6ba178d8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74232d69-1a8c-449d-8e8e-85488e6cc8f8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:636556f6-2987-984f-e053-2991aa0a201a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:225a87fb-d353-4ee7-bd08-14d631ff6b16 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe7ca564-16b8-4c54-aa09-3e2ed0c2596a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61b9ca82-7d41-4f49-b4a0-549c9473c447 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cd92b83-075e-b069-e063-6294a90a9fff (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac9aa10d-cd52-4ac9-a01d-e3cbf14d4913 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f71ba5e-7bd6-409a-80c6-2f22d975aefc (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec928ee5-0809-4ba5-82ca-ecfed99ebb5a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74620be9-5120-491a-a171-e50612c06541 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c044f774-783f-4920-a8a1-6d4b1b3820c1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e180dc7-c871-4efc-8755-cae882976c8d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:106b33e3-b199-e555-e063-6294a90a5af5 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50df9f09-aa2f-495d-a25c-7c5c0fdffcf0 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:850566b1-0c8e-42bc-85fa-c8ee710f34ba (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11b43a17-8038-462b-8902-259431ad5256 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb6a6199-bb70-476e-a2a2-b7594c9c001a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e66665e8-22eb-f5cd-e053-2a95a90a72e4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ef9e90-6ff0-4ee5-86a3-1efee9c36789 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d9397c-f8a2-42d6-88ca-55060b1d073a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:762c3007-b22f-4d35-87b4-191fec8b3a9a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a24255a3-88b1-47ef-90fc-51619a1c5a63 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43892b97-449d-45bc-bb09-29d47c655d65 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8809dc9-b99b-4d30-a7da-0bc21aa90f9c (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a620125-898a-47ba-9000-4295c3a3ad72 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a85be5-f746-418e-8e37-292703f16934 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43cffe12-304a-4e15-9512-94f812188f1a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7476adc-a940-4e76-a1dd-c418de493bc0 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9942f1a2-f66d-4d9e-9794-49bee8abf5ab (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e2f2025-0350-40c4-ab42-3b57f3d105a6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eed8cfeb-6ec7-4914-b8e0-a5c3d623c9a4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ca6a648-fc67-4cf8-a1f7-787c9574e3a1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ced821f-19a6-4c7e-e063-6394a90adb80 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09a5d332-347b-e73d-e063-6294a90a67ed (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdb9e7cf-bfbb-48b4-a8be-9038820d8279 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f276d9fe-a685-4d99-ad82-d4452ef4ba98 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7137458-0db3-7ecd-e053-6394a90a5f95 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e7ecef-f360-4987-a4f5-933214130ab2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9041cc05-29d2-41ca-a368-e953bf3443b5 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6cc3b99-2c0f-4d8a-8393-ec042ed7c892 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e9b4421-bc43-4a77-b49b-e3f53d1e0f01 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f317de31-495c-4268-8171-89534bf1dd36 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbfda3a5-5602-6e47-e053-2995a90ac07b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:839af3af-4040-4cf4-8d4a-881a053514cc (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e935265-d0fc-4223-835f-72426eeea6c4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1d09c53-5eb9-0b7c-e977-e2a602e84e5f (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2a0c48-7fc4-4760-b465-a79299876e6e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cdb473a-e6d5-48e8-e053-2a91aa0aaeb7 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3418eb02-117e-a71a-e063-6394a90a826e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de671934-25a8-4df6-b7a1-97e0337e9e2b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51abce7b-e3d1-44b5-bccc-d463150d0bba (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14869f9e-6a66-4f75-b0fc-4d808b1ee85e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70293a05-d314-43fa-a2b1-398cfb39edf8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a24de7-8ffe-48af-873f-10fdcd5551d1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e02f5fad-6482-4d5d-91c5-0ae6b0ce15b8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc8c9c5-a81a-4fb8-a8a4-bc717318c8a6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:609e97e5-ebc7-4268-84ea-f279284c89e2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ca03c9e-edc8-4c7f-89ee-f2346ea8c067 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb1606ea-1cff-46fd-b8e5-8135da76436c (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56616fc9-f3f7-8e0a-22c8-a6af106e6b1d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
When given as an immediate release oral formulation, the absolute bioavailability (compared to intravenous administration) of diltiazem is approximately 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc02db0f-5311-4b61-896e-bfe340832735 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74bab197-f719-48c0-ac84-c0cf0087b45a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8c8dd18-9d95-4068-9762-bec1eb1bc25c (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b150a6-4c8d-49c8-88df-f3606c335472 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe790439-85d4-4cd8-a385-149ea3442a38 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:976d9dd0-4f11-4439-b84e-0c0f0e018d8b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69ca7cae-fdf3-413a-900b-95cf6e9e7b63 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178eec1f-1d4d-4a38-b66a-d3ba3de06c3d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c5c1ed-1a9d-494c-b798-9da09ba1fe1b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a469b24a-fbec-4a2d-8b4c-b62c2b2c66f6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:196fc367-330e-4d15-b1d6-084ad3f97ae7 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f17187-e958-106b-e053-2a95a90a54d8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:090aa3a9-910e-4f96-b748-783109aa96e6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22e653e5-4122-4d7d-b9ad-0bdc1390fb40 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab38794a-914d-4bcd-9c6d-1578aa10041a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d594530-885f-45c7-b8a5-fd7e503ff83f (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb32d681-9a83-431e-9984-a5cee2c94852 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:465dbab3-f201-4441-8f55-92a843b5134f (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31e63a95-9e62-01c8-e063-6294a90af0e1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec7e93b8-666c-4d2f-8d08-07931e09f748 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:355f560a-8ebb-4661-ad74-2a22f707d7f8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0089fc7a-a7aa-4873-b699-39a1b21616ca (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54b0b11d-adc0-4afb-e054-00144ff88e88 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70f167a1-ec7f-4969-b446-166af3e52c05 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64401d2a-bd5b-43fd-879a-e9d16345e827 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bce61158-201d-458c-be0c-9bdd2d3a0bec (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
12.3 Pharmacokinetics Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous administration) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e99e1446-9c85-478c-9e23-a5f4104bbd22 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29febd6-5a27-eb83-e053-2a95a90a5b7d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e04232-b3da-48e8-a944-5f4f97a508df (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%.
50%
- Numeric value
- 50
- Unit
- %
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bae87a5-2137-467e-a1ad-79b2bc075e07 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Administration of diltiazem concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects and bioavailability of propranolol was increased approximately 50%.
Projected row 442
- Medicine slug
- diltiazem
- Compared field
- halfLife
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 111
- Source count
- 111
- Agreement rate
- 0.54955
- Recorded readings
20 hours
- Numeric value
- 20
- Unit
- hours
- Source records
- 61
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 61 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2dc2b889-8443-4f7f-83be-86c68e179804 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1042fa13-e6af-46b9-8008-6c941f0978b1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56573e9d-7bd2-694c-cd6d-26039590e548 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5460158f-7782-45f4-89b1-f84e6ba178d8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74232d69-1a8c-449d-8e8e-85488e6cc8f8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe7ca564-16b8-4c54-aa09-3e2ed0c2596a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:61b9ca82-7d41-4f49-b4a0-549c9473c447 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ac9aa10d-cd52-4ac9-a01d-e3cbf14d4913 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6f71ba5e-7bd6-409a-80c6-2f22d975aefc (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec928ee5-0809-4ba5-82ca-ecfed99ebb5a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c044f774-783f-4920-a8a1-6d4b1b3820c1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3e180dc7-c871-4efc-8755-cae882976c8d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:850566b1-0c8e-42bc-85fa-c8ee710f34ba (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:11b43a17-8038-462b-8902-259431ad5256 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb6a6199-bb70-476e-a2a2-b7594c9c001a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e66665e8-22eb-f5cd-e053-2a95a90a72e4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c1ef9e90-6ff0-4ee5-86a3-1efee9c36789 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e6d9397c-f8a2-42d6-88ca-55060b1d073a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:762c3007-b22f-4d35-87b4-191fec8b3a9a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43892b97-449d-45bc-bb09-29d47c655d65 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c8809dc9-b99b-4d30-a7da-0bc21aa90f9c (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3a620125-898a-47ba-9000-4295c3a3ad72 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:04a85be5-f746-418e-8e37-292703f16934 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7476adc-a940-4e76-a1dd-c418de493bc0 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1e2f2025-0350-40c4-ab42-3b57f3d105a6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eed8cfeb-6ec7-4914-b8e0-a5c3d623c9a4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bdb9e7cf-bfbb-48b4-a8be-9038820d8279 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7137458-0db3-7ecd-e053-6394a90a5f95 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9041cc05-29d2-41ca-a368-e953bf3443b5 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a6cc3b99-2c0f-4d8a-8393-ec042ed7c892 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0e9b4421-bc43-4a77-b49b-e3f53d1e0f01 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f317de31-495c-4268-8171-89534bf1dd36 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:dbfda3a5-5602-6e47-e053-2995a90ac07b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:839af3af-4040-4cf4-8d4a-881a053514cc (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5e935265-d0fc-4223-835f-72426eeea6c4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de2a0c48-7fc4-4760-b465-a79299876e6e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:7cdb473a-e6d5-48e8-e053-2a91aa0aaeb7 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:de671934-25a8-4df6-b7a1-97e0337e9e2b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70293a05-d314-43fa-a2b1-398cfb39edf8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e02f5fad-6482-4d5d-91c5-0ae6b0ce15b8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cc8c9c5-a81a-4fb8-a8a4-bc717318c8a6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:609e97e5-ebc7-4268-84ea-f279284c89e2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1ca03c9e-edc8-4c7f-89ee-f2346ea8c067 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:56616fc9-f3f7-8e0a-22c8-a6af106e6b1d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e8c8dd18-9d95-4068-9762-bec1eb1bc25c (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fe790439-85d4-4cd8-a385-149ea3442a38 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:976d9dd0-4f11-4439-b84e-0c0f0e018d8b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:178eec1f-1d4d-4a38-b66a-d3ba3de06c3d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d9c5c1ed-1a9d-494c-b798-9da09ba1fe1b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a469b24a-fbec-4a2d-8b4c-b62c2b2c66f6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c9f17187-e958-106b-e053-2a95a90a54d8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:090aa3a9-910e-4f96-b748-783109aa96e6 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:22e653e5-4122-4d7d-b9ad-0bdc1390fb40 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3d594530-885f-45c7-b8a5-fd7e503ff83f (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bb32d681-9a83-431e-9984-a5cee2c94852 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:465dbab3-f201-4441-8f55-92a843b5134f (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:355f560a-8ebb-4661-ad74-2a22f707d7f8 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:0089fc7a-a7aa-4873-b699-39a1b21616ca (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:54b0b11d-adc0-4afb-e054-00144ff88e88 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:70f167a1-ec7f-4969-b446-166af3e52c05 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bce61158-201d-458c-be0c-9bdd2d3a0bec (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Total radioactivity measurement following short IV administration in healthy volunteers suggests the presence of other unidentified metabolites, which attain higher concentrations than those of diltiazem and are more slowly eliminated; half-life of total radioactivity is about 20 hours compared to 2 to 5 hours for diltiazem.
3.0 to 4.5 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 33
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 33 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:636556f6-2987-984f-e053-2991aa0a201a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:225a87fb-d353-4ee7-bd08-14d631ff6b16 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2cd92b83-075e-b069-e063-6294a90a9fff (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74620be9-5120-491a-a171-e50612c06541 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c7c6a74e-5f73-4265-a0e0-8fd2cd26909e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:106b33e3-b199-e555-e063-6294a90a5af5 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:50df9f09-aa2f-495d-a25c-7c5c0fdffcf0 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a24255a3-88b1-47ef-90fc-51619a1c5a63 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c567fe7e-887e-4291-a0d1-2dd3f25cbf25 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9942f1a2-f66d-4d9e-9794-49bee8abf5ab (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6ca6a648-fc67-4cf8-a1f7-787c9574e3a1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:2ced821f-19a6-4c7e-e063-6394a90adb80 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:09a5d332-347b-e73d-e063-6294a90a67ed (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f276d9fe-a685-4d99-ad82-d4452ef4ba98 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3e7ecef-f360-4987-a4f5-933214130ab2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:862d65cb-a732-4786-b569-bad2eaafddfd (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f1d09c53-5eb9-0b7c-e977-e2a602e84e5f (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3418eb02-117e-a71a-e063-6394a90a826e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:51abce7b-e3d1-44b5-bccc-d463150d0bba (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:14869f9e-6a66-4f75-b0fc-4d808b1ee85e (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f6a24de7-8ffe-48af-873f-10fdcd5551d1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fb1606ea-1cff-46fd-b8e5-8135da76436c (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:fc02db0f-5311-4b61-896e-bfe340832735 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:88b150a6-4c8d-49c8-88df-f3606c335472 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:69ca7cae-fdf3-413a-900b-95cf6e9e7b63 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:196fc367-330e-4d15-b1d6-084ad3f97ae7 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:58eeb8bc-91d0-4cf8-a0d7-be3548d92196 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:31e63a95-9e62-01c8-e063-6294a90af0e1 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ec7e93b8-666c-4d2f-8d08-07931e09f748 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:64401d2a-bd5b-43fd-879a-e9d16345e827 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e99e1446-9c85-478c-9e23-a5f4104bbd22 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f29febd6-5a27-eb83-e053-2a95a90a5b7d (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:76e04232-b3da-48e8-a944-5f4f97a508df (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.
3.4 hours
- Numeric value
- 3.4
- Unit
- hours
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d75325-d935-ba54-e063-6394a90aade2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59464700-f7f1-6ab0-e063-6394a90aa778 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453b73bd-c52d-4d72-a0b3-47588e723e0b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bba03666-ff4f-4bf6-fa92-78e1ec2d9073 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bae87a5-2137-467e-a1ad-79b2bc075e07 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2942d7-f4d0-2d77-e063-6294a90a74ad (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d51c0f6-26b7-4220-83fb-4e736b289e64 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:734beeef-3968-4137-af2c-276e8a9317df (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f69371d-3ede-285d-e053-2a95a90a6e42 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d962ab-6cd4-43a1-a8fa-fb6548ac2a08 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life is approximately 3.4 hours.
3 to 4.5 hours
- Numeric value
- 3
- Unit
- hours
- Source records
- 7
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 7 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:d88e3546-3984-4dc9-893a-a29e95804550 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1278cd76-b8e9-42d9-ad19-6858e72cf9f2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:43cffe12-304a-4e15-9512-94f812188f1a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:eebf29fe-ce22-4482-b850-5854550bf2c4 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3 to 4.5 h.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:74bab197-f719-48c0-ac84-c0cf0087b45a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4b4e53e-fc99-4f34-abc2-57e4f28aff84 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life of diltiazem is approximately 3 to 4.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:ab38794a-914d-4bcd-9c6d-1578aa10041a (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The plasma elimination half-life following single or multiple drug administration is approximately 3 to 4.5 hours.
Projected row 443
- Medicine slug
- diltiazem
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 111
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
40%
- Numeric value
- 40
- Unit
- %
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d75325-d935-ba54-e063-6394a90aade2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59464700-f7f1-6ab0-e063-6394a90aa778 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha1-acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453b73bd-c52d-4d72-a0b3-47588e723e0b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bba03666-ff4f-4bf6-fa92-78e1ec2d9073 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 –acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bae87a5-2137-467e-a1ad-79b2bc075e07 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2942d7-f4d0-2d77-e063-6294a90a74ad (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d51c0f6-26b7-4220-83fb-4e736b289e64 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:734beeef-3968-4137-af2c-276e8a9317df (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f69371d-3ede-285d-e053-2a95a90a6e42 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d962ab-6cd4-43a1-a8fa-fb6548ac2a08 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
In vitro studies suggest alpha 1 -acid glycoprotein binds approximately 40% of the drug at clinically significant concentrations.
Projected row 444
- Medicine slug
- diltiazem
- Compared field
- volumeOfDistribution
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 111
- Source count
- 10
- Agreement rate
- 1
- Recorded readings
305 L
- Numeric value
- 305
- Unit
- L
- Source records
- 10
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 10 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:41d75325-d935-ba54-e063-6394a90aade2 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:59464700-f7f1-6ab0-e063-6394a90aa778 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:453b73bd-c52d-4d72-a0b3-47588e723e0b (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:bba03666-ff4f-4bf6-fa92-78e1ec2d9073 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem hydrochloride is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:8bae87a5-2137-467e-a1ad-79b2bc075e07 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
Distribution The volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:3f2942d7-f4d0-2d77-e063-6294a90a74ad (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9d51c0f6-26b7-4220-83fb-4e736b289e64 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:734beeef-3968-4137-af2c-276e8a9317df (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9f69371d-3ede-285d-e053-2a95a90a6e42 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem is approximately 305 L.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8d962ab-6cd4-43a1-a8fa-fb6548ac2a08 (opens source in a new tab)
Diltiazem label
Version not recorded · Effective date not recorded
The apparent volume of distribution of diltiazem hydrochloride is approximately 305 L.
Projected row 445
- Medicine slug
- dimethyl
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 1
- Recorded readings
1 hour
- Numeric value
- 1
- Unit
- hours
- Source records
- 19
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 19 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3677dce-a44b-481f-8a76-9ff3a4d42105 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3002b6a-841e-4247-9155-3acfb30cabcd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39150ef0-ba48-4719-b7fd-9beb4d4ad3ce (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7ef9b9e-d97a-4a56-b792-a1a255613156 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e12d8fee-bd18-4f84-8333-c890f1d132b7 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a200c1-f25a-4aa8-8770-06182fdeda9d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c42107a-2a42-4263-97b6-ae0d7675c92a (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:074d2820-6cb4-437a-8f6f-a21cb0a8ee02 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665d7e74-036c-5f68-5b67-ab84b9b49151 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f65da9-f5f4-4161-aded-c23b16fd49ed (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00dcf89-59d3-9ab2-fd9b-16b9ec2d677b (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f56f42-2247-41a9-a1e9-07c3af50e549 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08f3a987-6571-42b3-854b-186d782b4494 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b19329-5c1d-4879-85a9-36ffec3ff5cb (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8e5184d-5d1d-0a89-e053-2995a90a2d6d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b856ac70-71cd-477b-95b1-0a6132c260e8 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5361d5c6-c3eb-88e6-e063-6294a90ac08c (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7626c6-2b1b-4865-818c-0c79c18c049d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
The terminal half-life of MMF is approximately 1 hour and no circulating MMF is present at 24 hours in the majority of individuals.
Projected row 446
- Medicine slug
- dimethyl
- Compared field
- proteinBinding
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 0.842105
- Recorded readings
27-45%
- Numeric value
- 27
- Unit
- %
- Source records
- 16
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 16 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3677dce-a44b-481f-8a76-9ff3a4d42105 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27-45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3002b6a-841e-4247-9155-3acfb30cabcd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39150ef0-ba48-4719-b7fd-9beb4d4ad3ce (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e12d8fee-bd18-4f84-8333-c890f1d132b7 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c42107a-2a42-4263-97b6-ae0d7675c92a (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27-45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:074d2820-6cb4-437a-8f6f-a21cb0a8ee02 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665d7e74-036c-5f68-5b67-ab84b9b49151 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27-45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f65da9-f5f4-4161-aded-c23b16fd49ed (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00dcf89-59d3-9ab2-fd9b-16b9ec2d677b (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f56f42-2247-41a9-a1e9-07c3af50e549 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27-45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08f3a987-6571-42b3-854b-186d782b4494 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27-45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b19329-5c1d-4879-85a9-36ffec3ff5cb (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8e5184d-5d1d-0a89-e053-2995a90a2d6d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27-45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b856ac70-71cd-477b-95b1-0a6132c260e8 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5361d5c6-c3eb-88e6-e063-6294a90ac08c (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 to 45% and independent of concentration.
27 %
- Numeric value
- 27
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7ef9b9e-d97a-4a56-b792-a1a255613156 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27 % to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a200c1-f25a-4aa8-8770-06182fdeda9d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27% to 45% and independent of concentration.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7626c6-2b1b-4865-818c-0c79c18c049d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Human plasma protein binding of MMF is 27% to 45% and independent of concentration.
Projected row 447
- Medicine slug
- dimethyl
- Compared field
- tMax
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 0.947368
- Recorded readings
2-2.5 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 18
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 18 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3677dce-a44b-481f-8a76-9ff3a4d42105 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3002b6a-841e-4247-9155-3acfb30cabcd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39150ef0-ba48-4719-b7fd-9beb4d4ad3ce (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e12d8fee-bd18-4f84-8333-c890f1d132b7 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a200c1-f25a-4aa8-8770-06182fdeda9d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c42107a-2a42-4263-97b6-ae0d7675c92a (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:074d2820-6cb4-437a-8f6f-a21cb0a8ee02 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665d7e74-036c-5f68-5b67-ab84b9b49151 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f65da9-f5f4-4161-aded-c23b16fd49ed (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00dcf89-59d3-9ab2-fd9b-16b9ec2d677b (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f56f42-2247-41a9-a1e9-07c3af50e549 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median Tmax of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08f3a987-6571-42b3-854b-186d782b4494 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b19329-5c1d-4879-85a9-36ffec3ff5cb (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8e5184d-5d1d-0a89-e053-2995a90a2d6d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median Tmax of MMF is 2-2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b856ac70-71cd-477b-95b1-0a6132c260e8 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5361d5c6-c3eb-88e6-e063-6294a90ac08c (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7626c6-2b1b-4865-818c-0c79c18c049d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 to 2.5 hours.
2 hours
- Numeric value
- 2
- Unit
- hours
- Source records
- 1
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 1 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7ef9b9e-d97a-4a56-b792-a1a255613156 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Absorption The median T max of MMF is 2 hours to 2.5 hours.
Projected row 448
- Medicine slug
- dimethyl
- Compared field
- volumeOfDistribution
- Comparison state
- insufficient_context
- Reason codes
- STRUCTURED_CONTEXT_MISSING
- Documents examined
- 19
- Source count
- 19
- Agreement rate
- 0.894737
- Recorded readings
73 L
- Numeric value
- 73
- Unit
- L
- Source records
- 17
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 17 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a3677dce-a44b-481f-8a76-9ff3a4d42105 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f3002b6a-841e-4247-9155-3acfb30cabcd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:39150ef0-ba48-4719-b7fd-9beb4d4ad3ce (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e7ef9b9e-d97a-4a56-b792-a1a255613156 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:e12d8fee-bd18-4f84-8333-c890f1d132b7 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6c42107a-2a42-4263-97b6-ae0d7675c92a (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:074d2820-6cb4-437a-8f6f-a21cb0a8ee02 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:665d7e74-036c-5f68-5b67-ab84b9b49151 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c3f65da9-f5f4-4161-aded-c23b16fd49ed (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b00dcf89-59d3-9ab2-fd9b-16b9ec2d677b (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:48f56f42-2247-41a9-a1e9-07c3af50e549 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:08f3a987-6571-42b3-854b-186d782b4494 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f8ada3e3-55c0-43e3-95b9-c6d11ffc42dd (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:c2b19329-5c1d-4879-85a9-36ffec3ff5cb (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b8e5184d-5d1d-0a89-e053-2995a90a2d6d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b856ac70-71cd-477b-95b1-0a6132c260e8 (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:5361d5c6-c3eb-88e6-e063-6294a90ac08c (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 and 73 L in healthy subjects.
53 L
- Numeric value
- 53
- Unit
- L
- Source records
- 2
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 2 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:b4a200c1-f25a-4aa8-8770-06182fdeda9d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 L and 73 L in healthy subjects.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:4c7626c6-2b1b-4865-818c-0c79c18c049d (opens source in a new tab)
Dimethyl label
Version not recorded · Effective date not recorded
Distribution The apparent volume of distribution of MMF varies between 53 L and 73 L in healthy subjects.
Projected row 449
- Medicine slug
- dipyridamole
- Compared field
- halfLife
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 4
- Agreement rate
- 1
- Recorded readings
10 hours
- Numeric value
- 10
- Unit
- hours
- Source records
- 4
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 4 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:004bada0-dbf7-4a94-8792-6833d7eeda2b (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:226099e2-70bb-4b9b-bb52-c20fbca2aec5 (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:a18b2af5-7c4a-4b7f-92c7-8a76e34da373 (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:f7ffd78a-e93a-40f4-8193-2d6ab4dafd00 (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The beta half-life (the terminal decline in plasma concentration) is approximately 10 hours.
Projected row 450
- Medicine slug
- dipyridamole
- Compared field
- proteinBinding
- Comparison state
- agree
- Reason codes
- COMPATIBLE_VALUES_OVERLAP
- Documents examined
- 7
- Source count
- 3
- Agreement rate
- 1
- Recorded readings
99%
- Numeric value
- 99
- Unit
- %
- Source records
- 3
Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.
Show all 3 source records
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:9bd34108-9d98-c4ca-e053-2995a90a2bc8 (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The average plasma protein binding of dipyridamole is approximately 99%, primarily to α1-glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:1a2c0a9a-c637-4485-ad4b-0b6d0b05fa20 (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The average plasma protein binding of dipyridamole is approximately 99%, primarily toa1-glycoprotein.
- FDA_LABELRetrieved 2026-08-30FDA_LABEL:6093dcd9-82d2-414f-8507-eda22c14f626 (opens source in a new tab)
Dipyridamole label
Version not recorded · Effective date not recorded
The average plasma protein binding of dipyridamole is approximately 99%, primarily to α 1 -glycoprotein.
Access
Query or download the projection
GET /api/datasets/source-consensus?limit=10&offset=440Allowed query parameters
- q
- Case-insensitive text search over the public fields named for this dataset.
- state
- Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
- field
- Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
- limit / offset
- Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.
Reuse and corrections
Keep the boundary attached
CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.
Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.